Acupuncture for chronic sciatica: protocol for a multicenter randomised controlled trial

• Published in: BMJ open Vol. 12; no. 5; p. e054566
• Main Authors: Yu, Fang-Ting, Liu, Cun-Zhi, Ni, Guang-Xia, Cai, Guo-Wei, Liu, Zhi-Shun, Zhou, Xiao-Qing, Ma, Chao-Yang, Meng, Xiu-Li, Tu, Jian-Feng, Li, He-Wen, Yang, Jing-Wen, Yan, Shi-Yan, Fu, Hai-Yang, Xu, Wen-Tao, Li, Jing, Xiang, Hong-Chun, Sun, Tian-Heng, Zhang, Beng, Li, Mei-Hua, Wan, Wen-Jun, He, Cheng, Ji, Xiao-Lan, Zhu, Wei, Shi, Guang-Xia, Wang, Li-Qiong
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 17.05.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Acupuncture; Back pain; Chinese medicine; Clinical trials; Complementary Medicine; Gallbladder; Hospitals; Neurological pain; PAIN MANAGEMENT; Surgery; Beijing China; China; Clinical trials; PAIN MANAGEMENT; COMPLEMENTARY MEDICINE; Neurological pain
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2021-054566

BackgroundChronic Sciatica is a disabling condition causing considerable medical, social and financial implications. Currently, there is no recognised long-term effective treatment to alleviate sciatica. Acupuncture has been widely used for treating chronic pains with persistent analgesic effects. We aim to evaluate the efficacy and safety of acupuncture for chronic sciatica with follow-up in 52 weeks.Methods and analysisThis is a multicenter randomised sham-controlled trial. A total of 216 patients with chronic sciatica will be enrolled and randomly assigned to the acupuncture or sham acupuncture group. There will be 10 treatment sessions applied in 4 weeks with frequency decreased over time. Patients will complete follow-ups during 52 weeks. The primary outcomes are changes in leg pain intensity and disability from baseline to week 4. Secondary outcomes include back pain intensity, frequency and bothersomeness, quality of life, and global perceived effect. Adverse events will be recorded in detail.Ethics and disseminationEthical approval of this trial was granted from the ethics committee of Beijing University of Chinese Medicine and all study centres (No. 2020BZYLL0803). Written informed consent will be obtained from enrolled patients. Trial results will be disseminated in peer-reviewed publications.Trial registration numberChiCTR2100044585 (Chinese Clinical Trial Registry, http://www.chictr.org.cn, registered on 24 March 2021); preresults.